The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...
The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY ...
Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...
The approval marks the introduction of the first mRNA RSV vaccine in Canada. Credit: MargJohnsonVA via Shutterstock. Moderna has received Health Canada’s approval for its respiratory syncytial virus ...
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
He added that mRNA vaccine technology, made famous during the Covid-19 pandemic, has a major role in future therapies and is "actually at the heart" of breakthrough therapies like Spinraza and Qalsody ...
When it comes to selecting Cabinet members for President-elect Donald Trump's second term, you can't have too much of a good thing.
A new large study of children in California shows that unvaccinated kids are at a much higher risk of developing multisystem ...
PHILADELPHIA — The same technology that saved millions of lives during the COVID-19 pandemic appears to hold promise against another scourge of infectious disease, according to new research from the ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback